BR0306701A - Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal - Google Patents
Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um salInfo
- Publication number
- BR0306701A BR0306701A BR0306701-7A BR0306701A BR0306701A BR 0306701 A BR0306701 A BR 0306701A BR 0306701 A BR0306701 A BR 0306701A BR 0306701 A BR0306701 A BR 0306701A
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- salts
- compound
- alkyl
- preparing
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 11
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- -1 Compound Salt Chemical class 0.000 title abstract 2
- 159000000007 calcium salts Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 229910052736 halogen Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910003002 lithium salt Inorganic materials 0.000 abstract 1
- 159000000002 lithium salts Chemical class 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229910021645 metal ion Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003751 zinc Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTO, SAL DO COMPOSTO, SAL DE CáLCIO, MéTODO DE PREPARAçãO DE UM SAL, COMPOSIçãO FARMACêUTICA, MéTODO DE PREPARAçãO DE UMA COMPOSIçãO, E, USO DE UM SAL". A invenção atual refere-se a um composto da fórmula geral (I) onde: R1 é selecionado do grupo consistindo de (C1-C6)alcoxi(C1-C6)alquila que poderá ser substituído por uma (C1-C6)alcoxila, fenil-(C1-C6)-alquila e feniloxi- (C1-C6 )-alquila ou onde o grupo fenila poderá ser substituído por (C1-C6)alquila, (C1-C6)alcoxila ou halogênio, e naftil-(C1-C6)-alquila, R2 e R3 são ambos independentemente hidrogênio ou halogênio, R4 é um grupo de formação de éster bio-instável, como um sal metálico farmaceuticamente aceitável, caracterizado pelo fato de que o sal é selecionado do grupo consistindo de sal de lítio e sais de íons metálicos bivalentes, tais como os sais de magnésio, cálcio e zinco. A invenção refere-se ainda a um método para a preparação dos sais acima, a uma composição farmacêutica composta dos sais da invenção, ao uso destes sais no tratamento de desordens ou hipertensão do coração, na melhoria do fluxo de sangue gastrintestinal ou no tratamento e profilaxia de doenças cardíacas induzidas por adriamicina e drogas anticâncer comparáveis e a sais de S-<244>-metilbenzilamina cristalina dos compostos da fórmula (I) que são úteis como um intermediário na produção dos sais acima mencionados.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02075621 | 2002-01-16 | ||
| NL1019762 | 2002-01-17 | ||
| PCT/EP2003/000515 WO2003059939A1 (en) | 2002-01-16 | 2003-01-15 | Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306701A true BR0306701A (pt) | 2004-12-28 |
Family
ID=26077601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306701-7A BR0306701A (pt) | 2002-01-16 | 2003-01-15 | Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6998398B2 (pt) |
| EP (1) | EP1468010A1 (pt) |
| JP (1) | JP4384495B2 (pt) |
| KR (1) | KR100979077B1 (pt) |
| CN (1) | CN100591689C (pt) |
| AU (1) | AU2003206755B2 (pt) |
| BR (1) | BR0306701A (pt) |
| CA (1) | CA2473447A1 (pt) |
| HR (1) | HRP20040560A2 (pt) |
| IL (1) | IL162645A0 (pt) |
| MX (1) | MXPA04006887A (pt) |
| NO (1) | NO330528B1 (pt) |
| PL (1) | PL371511A1 (pt) |
| RU (1) | RU2303041C2 (pt) |
| WO (1) | WO2003059939A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050009031A (ko) * | 2003-07-15 | 2005-01-24 | 엘지전자 주식회사 | 1회 기록 가능한 광디스크 및 광디스크의 관리정보 기록방법 |
| SA04250283B1 (ar) * | 2003-09-26 | 2008-05-26 | سولفاي فارماسيتيكالز جي أم بي أتش | مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid |
| DE602004010172T2 (de) | 2003-11-18 | 2008-09-11 | Solvay Pharmaceuticals Gmbh | Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| RU2410118C2 (ru) | 2004-12-15 | 2011-01-27 | Зольвай Фармасьютиклз Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ |
| US20060159748A1 (en) * | 2004-12-23 | 2006-07-20 | Rajesh Jain | Oral immediate release formulation of a poorly water-soluble active substance |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| WO2007054975A1 (en) * | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
| PL424453A1 (pl) | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| DE19750002A1 (de) * | 1997-11-12 | 1999-05-20 | Solvay Pharm Gmbh | Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
-
2003
- 2003-01-15 CN CN03802391A patent/CN100591689C/zh not_active Expired - Fee Related
- 2003-01-15 CA CA002473447A patent/CA2473447A1/en not_active Abandoned
- 2003-01-15 RU RU2004124840/04A patent/RU2303041C2/ru not_active IP Right Cessation
- 2003-01-15 WO PCT/EP2003/000515 patent/WO2003059939A1/en not_active Ceased
- 2003-01-15 MX MXPA04006887A patent/MXPA04006887A/es active IP Right Grant
- 2003-01-15 HR HR20040560A patent/HRP20040560A2/hr not_active Application Discontinuation
- 2003-01-15 BR BR0306701-7A patent/BR0306701A/pt not_active Application Discontinuation
- 2003-01-15 EP EP03704436A patent/EP1468010A1/en not_active Withdrawn
- 2003-01-15 IL IL16264503A patent/IL162645A0/xx not_active IP Right Cessation
- 2003-01-15 JP JP2003560041A patent/JP4384495B2/ja not_active Expired - Lifetime
- 2003-01-15 KR KR1020047010938A patent/KR100979077B1/ko not_active Expired - Fee Related
- 2003-01-15 PL PL03371511A patent/PL371511A1/xx not_active Application Discontinuation
- 2003-01-15 AU AU2003206755A patent/AU2003206755B2/en not_active Ceased
-
2004
- 2004-07-14 US US10/890,392 patent/US6998398B2/en not_active Expired - Fee Related
- 2004-08-06 NO NO20043295A patent/NO330528B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005520809A (ja) | 2005-07-14 |
| RU2303041C2 (ru) | 2007-07-20 |
| HRP20040560A2 (en) | 2004-10-31 |
| MXPA04006887A (es) | 2004-12-06 |
| KR20040089106A (ko) | 2004-10-20 |
| US6998398B2 (en) | 2006-02-14 |
| CA2473447A1 (en) | 2003-07-24 |
| HK1072946A1 (zh) | 2005-09-16 |
| KR100979077B1 (ko) | 2010-08-31 |
| EP1468010A1 (en) | 2004-10-20 |
| CN100591689C (zh) | 2010-02-24 |
| US20050038012A1 (en) | 2005-02-17 |
| WO2003059939A1 (en) | 2003-07-24 |
| AU2003206755B2 (en) | 2008-07-17 |
| CN1617883A (zh) | 2005-05-18 |
| RU2004124840A (ru) | 2006-01-20 |
| PL371511A1 (en) | 2005-06-27 |
| IL162645A0 (en) | 2005-11-20 |
| NO20043295L (no) | 2004-08-06 |
| JP4384495B2 (ja) | 2009-12-16 |
| NO330528B1 (no) | 2011-05-09 |
| AU2003206755A1 (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60315674D1 (de) | Neue imidazopyridine und ihre verwendung | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| EA200900066A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| WO2008019967A3 (en) | Phenyl, pyridine and quinoline derivatives | |
| MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
| ATE517882T1 (de) | Chinolinderivate | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| BR0210384A (pt) | Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença | |
| CN105001165A (zh) | 取代的二氨基嘧啶其组合物，和用其治疗的方法 | |
| WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| UA89123C2 (ru) | Производные пиримидина для лечения абнормального роста клеток | |
| NO20050134L (no) | Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse | |
| EA200500096A1 (ru) | Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ | |
| MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| BR0306701A (pt) | Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| TW200616979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| WO2007125398A3 (en) | : sulfonamide compounds as antagonists of the n-type calcium channel | |
| MX2010003983A (es) | 5,6-diarilpiridinas sustituidas en la posicion 2 y 3, su preparacion y su uso terapeutico. | |
| BR0308419A (pt) | Derivados de azetidina como antagonistas do receptor ccr-3 | |
| WO2008106125A3 (en) | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |